These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

221 related items for PubMed ID: 15261563

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Role of immunosuppressive therapy for the treatment of multiple sclerosis.
    Stankiewicz JM, Kolb H, Karni A, Weiner HL.
    Neurotherapeutics; 2013 Jan; 10(1):77-88. PubMed ID: 23271506
    [Abstract] [Full Text] [Related]

  • 9. Disease-modifying drugs for multiple sclerosis: a rapid and systematic review.
    Clegg A, Bryant J, Milne R.
    Health Technol Assess; 2000 Jan; 4(9):i-iv, 1-101. PubMed ID: 10944743
    [No Abstract] [Full Text] [Related]

  • 10. Azathioprine and methotrexate in multiple sclerosis.
    Fernández O, Fernández V, De Ramón E.
    J Neurol Sci; 2004 Aug 15; 223(1):29-34. PubMed ID: 15261557
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Management of isolated demyelinating episodes by North American neurologists.
    Tselis A, Chaturvedi S, Borsody M, Vaidya R.
    Can J Neurol Sci; 2007 Aug 15; 34(3):375-6. PubMed ID: 17803042
    [No Abstract] [Full Text] [Related]

  • 13. [Is immunosuppression a future therapeutic strategy for multiple sclerosis?].
    Edan G, Coustans M.
    Pathol Biol (Paris); 2000 Mar 15; 48(2):114-20. PubMed ID: 10815287
    [Abstract] [Full Text] [Related]

  • 14. Pixantrone (BBR2778): a new immunosuppressant in multiple sclerosis with a low cardiotoxicity.
    Gonsette RE, Dubois B.
    J Neurol Sci; 2004 Aug 15; 223(1):81-6. PubMed ID: 15261566
    [Abstract] [Full Text] [Related]

  • 15. The argument against the use of cyclophosphamide and mitoxantrone in the treatment of multiple sclerosis.
    Jeffery DR.
    J Neurol Sci; 2004 Aug 15; 223(1):41-6. PubMed ID: 15261559
    [Abstract] [Full Text] [Related]

  • 16. Combination therapy in multiple sclerosis.
    Conway D, Cohen JA.
    Lancet Neurol; 2010 Mar 15; 9(3):299-308. PubMed ID: 20170843
    [Abstract] [Full Text] [Related]

  • 17. Immunosuppressive treatment of multiple sclerosis.
    Carter JL, Rodriguez M.
    Mayo Clin Proc; 1989 Jun 15; 64(6):664-9. PubMed ID: 2473360
    [Abstract] [Full Text] [Related]

  • 18. Escalating immunotherapy of multiple sclerosis.Austrian-German- Swiss Multiple Sclerosis Therapy Consensus Group [MSTCG].
    Rieckmann P, Toyka KV.
    Eur Neurol; 1999 Jun 15; 42(3):121-7. PubMed ID: 10529535
    [Abstract] [Full Text] [Related]

  • 19. [Immunosuppressive treatment in neurological disorders].
    Aarli JA.
    Tidsskr Nor Laegeforen; 1973 Jun 30; 93(18):1395-7. PubMed ID: 4356438
    [No Abstract] [Full Text] [Related]

  • 20. [Immunosuppressants and multiple sclerosis].
    Ruiz-Peña JL, Izquierdo-Ayuso G.
    Rev Neurol; 1973 Jun 30; 35(4):373-80. PubMed ID: 12235571
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.